Protocol Schedules
Master reference of documented research protocol schedules. Each entry summarises timing, frequency, and duration ranges reported in research literature and community protocol references.
How to Read These Schedules
Schedules describe documented protocol references from published literature. Concentrations, frequencies, and durations vary by assay type, model system, and experimental design.
Neuropeptide
Pinealon
- Neuronal cultures: 24-48 hour exposure for viability endpoints
- Bioregulator research: 10-20 day course references in pineal function studies
- Retinal models: daily administration over 14-28 days in published research literature.
- Short tripeptide format studied for cell-penetrating properties
Neuropeptide
Epithalon (Epitalon)
- Bioregulator protocol literature commonly references 10-20 day courses with 4-6 month intervals
- Daily administration during active course phases in aging model research
- Cell senescence assays: 48-72 hour exposure for telomerase readouts
- Pineal studies: 14-30 day courses for melatonin enzyme markers
Growth Axis
Tesamorelin
- Investigational literature: daily administration over 12-26 weeks in defined cohorts
- Visceral adipose endpoints often measured at 12 and 26 week timepoints
- Pituitary cell research: single bolus and chronic exposure protocols
- Hepatocyte lipogenesis assays: 24-72 hour exposure windows
Growth Axis
Ipamorelin
- Standalone or combination: 1-3 daily administrations in 8-12 week research windows
- Pre-sleep dosing studied for nocturnal GH pulse research
- 5 days on / 2 days off cycling appears in community protocol references
- Somatotroph assays: bolus application with GH measurement at 15-60 minute intervals
Metabolic
SLU-PP-332
- Myocyte cultures: 24-72 hour exposure for gene expression endpoints
- Research literature: daily oral or systemic schedules over 3-6 weeks in published studies.
- Exercise-comparison studies: 4-week parallel protocol references
- Emerging compound - protocol standardisation still evolving in literature
Melanocortin
PT-141 (Bremelanotide)
- Receptor binding assays: single acute exposure at nM concentrations
- Pharmacology research: single-dose or limited repeat-dose protocols in defined cohorts
- Neuronal cultures: 1-24 hour exposure for second-messenger endpoints
- Investigational literature examines on-demand vs. scheduled administration designs
Longevity
NAD+
- Cell culture: acute bolus or continuous media supplementation at mM concentrations
- IV research literature: single sessions to weekly infusions over 4-8 weeks in defined cohorts
- Oral precursor studies (NR/NMN) often run 4-12 weeks; direct NAD+ IV protocols vary
- Aging model research: 2-4 week intervention windows for mitochondrial endpoint assays